Cargando…

Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer

BACKGROUND: Defects in programmed cell death, or apoptosis, are a hallmark of cancer. The anti-apoptotic B-cell lymphoma 2 (BCL-2) family proteins, including BCL-2, BCL-X(L), and MCL-1 have been characterized as key survival factors in multiple cancer types. Because cancer types with BCL2 and MCL1 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Haichao, Xue, John, Hessler, Paul, Tahir, Stephen K., Chen, Jun, Jin, Sha, Souers, Andrew J., Leverson, Joel D., Lam, Lloyd T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487849/ https://www.ncbi.nlm.nih.gov/pubmed/26134786 http://dx.doi.org/10.1186/s12943-015-0397-y

Ejemplares similares

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X(L)–BAX interaction
por: Saleh, Tareq, et al.
Publicado: (2020)

Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines
por: Lam, Lloyd T, et al.
Publicado: (2015)

Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors
por: Leverson, Joel D.
Publicado: (2015)

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X(L) Inhibitor
por: Wang, Le, et al.
Publicado: (2020)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it
por: Tahir, Stephen K., et al.
Publicado: (2017)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
por: Leverson, Joel D., et al.
Publicado: (2018)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA
por: Fairchild, Carter K., et al.
Publicado: (2021)

Bcl-x(L) is an oncogenic driver in colorectal cancer
por: Scherr, Anna-Lena, et al.
Publicado: (2016)

Differential Dependence on Beclin 1 for the Regulation of Pro-Survival Autophagy by Bcl-2 and Bcl-xL in HCT116 Colorectal Cancer Cells
por: Priault, Muriel, et al.
Publicado: (2010)

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
por: Krull, Jordan E., et al.
Publicado: (2020)

Physiological restraint of Bak by Bcl-x(L) is essential for cell survival
por: Lee, Erinna F., et al.
Publicado: (2016)

BCL-xL/BCL2L1 is a critical anti-apoptotic protein that promotes the survival of differentiating pancreatic cells from human pluripotent stem cells
por: Loo, Larry Sai Weng, et al.
Publicado: (2020)

Praf2 Is a Novel Bcl-xL/Bcl-2 Interacting Protein with the Ability to Modulate Survival of Cancer Cells
por: Vento, Maria Teresa, et al.
Publicado: (2010)

ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells
por: Parrondo, Ricardo, et al.
Publicado: (2013)

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
por: Osada, Naoki, et al.
Publicado: (2021)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

The Structural Biology of Bcl-x(L)
por: Lee, Erinna F., et al.
Publicado: (2019)

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X(L) dual inhibitor that induces Bax-dependent apoptosis
por: Yao, Weilong, et al.
Publicado: (2022)

Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2022)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Bcl-xL Promotes the Survival of Motor Neurons Derived from Neural Stem Cells
por: Wu, Yunqin, et al.
Publicado: (2023)

Bcl-w expression in colorectal adenocarcinoma
por: Wilson, J W, et al.
Publicado: (2000)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression
por: Yasuda, Yuto, et al.
Publicado: (2020)

Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival.
por: Ofner, D., et al.
Publicado: (1995)

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer
por: Scherr, Anna-Lena, et al.
Publicado: (2020)

Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression
por: Song, Yanfang, et al.
Publicado: (2021)

Bcl-xL DNAzymes promote radiosensitivity and chemosensitivity in colorectal cancer cells via enhancing apoptosis
por: Yu, Zhen, et al.
Publicado: (2022)

Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the mitochondrial outer membrane
por: Kaufmann, Thomas, et al.
Publicado: (2003)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-2 and Bcl-x(L) Suppress Glucose Signaling in Pancreatic β-Cells
por: Luciani, Dan S., et al.
Publicado: (2013)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

Alternative splicing of BCL-x is controlled by RBM25 binding to a G-quadruplex in BCL-x pre-mRNA
por: Le Sénéchal, Ronan, et al.
Publicado: (2023)

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL
por: Vikström, Ingela B, et al.
Publicado: (2016)

Loss of Bcl-G, a Bcl-2 family member, augments the development of inflammation-associated colorectal cancer
por: Nguyen, Paul M., et al.
Publicado: (2019)

The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma
por: Ghanem, M A, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_aj01kqbdb5pjiuc4a883rvqil3